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A B S T R A C T   
Background Growing concerns about the impact of coronavirus disease 2019 (COVID-19) will likely lead to 
increased mental health diagnoses and treatment. To provide a pre-COVID-19 baseline, we have examined an-
tidepressant prescribing trends for 5 years preceding COVID-19. 
Methods A retrospective analysis of anonymised data on medicines prescribed by GPs in England from the 
Open-Prescribing Database (January 2015 to December 2019) identified the 10 most prescribed antidepressant 
and, for comparison, cardiovascular medicines. 
Results Prescription items for the 10 most prescribed antidepressants rose 25% from 58 million (2015) to 72 
million (2019). Citalopram was the most prescribed antidepressant; prescriptions for sertraline rose fastest at 2 
million items year on year. Over the same period, costs for antidepressant prescribing fell 27.8%. Across all 
Clinical Commissioning Groups (CCGs) in England, antidepressant prescribing levels, adjusted for population 
were positively correlated with the index of multiple deprivation (IMD) score. In comparison, prescribing for the 
top 10 most prescribed cardiovascular medicines increased by 2.75% from 207 million (2015) to 213 million 
(2019) items. 
Limitations Anonymised data in the Open-Prescribing Database means no patient diagnoses or treatment plans 
are linked to this data. 
Conclusion Antidepressant prescribing, particularly sertraline, is increasing. Prescribing is higher in more 
deprived regions, but costs are falling to < 2% of all items prescribed. Absolute numbers of prescriptions for 
cardiovascular medicines are higher, likely reflecting the greater prevalence of cardiovascular disease, and are 
rising more slowly. This study will enable future work to look at the impact of COVID-19 on prescribing for 
mental health.   
1. Introduction 
According to the World Health Organization (WHO), depression af-
fects more than 264 million people and is a leading cause of disability 
worldwide (WHO, 2020). In 2014, the Adult Psychiatric Morbidity 
Survey showed an increase in the prevalence of depression in England to 
3.8 from 2.8% in 2000, alongside an increase in other mental health 
conditions such as anxiety which increased from 4.7 to 6.6% (McManus 
et al., 2016). In the UK, GP data on antidepressant prescribing showed a 
2-fold increase in the number of antidepressant prescriptions from 1975 
to 1998 (Middleton et al., 2001). A descriptive study using the general 
practice research databse (GPRD) reported that most antidepressant 
prescriptions were issued to patients receiving long-term treatment for 
depression or intermittent treatment (Moore et al., 2009). Public Health 
England recently reviewed National Health Service (NHS) community 
prescriptions in England reported to the NHS Business Services Au-
thority (NHSBSA) and showed that the proportion of adult residents in 
England receiving a prescription for antidepressants increased in the 
period 2015–2018 (Taylor et al., 2019). Interestingly, incidence of an-
tidepressant use varies across countries and indication. Antidepressant 
use in older adults has been reported to vary 24-fold by country, with the 
UK being among the lowest (Tamblyn et al. 2019). Tamblyn et al. (2019) 
reported that chronic pain was the most common potential treatment 
indication, with tricyclic antidepressants used most frequently in the 
UK. Concerns are expressed that rising prescribing represents 
over-diagnosis of depression and over-use of antidepressants (Mid-
dleton and Moncrieff, 2011; Spence, 2016). On the other hand, 
increasing prescriptions can be viewed as an increase in the number of 
patients on long term antidepressant treatment to reduce relapse rates 
(Moore et al., 2009). 
Abbreviations: CCG, Clinical Commissioning Group; COVID-19, coronavirus disease 2019; IMD, index of multiple deprivation; NHS, National Health Service; 
NHSBSA, NHS Business Services Authority; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and noradrenaline reuptake inhibitor. 
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There are growing concerns about the impact of coronavirus disease 
2019 (COVID-19) on mental health. This relates not only to the potential 
direct effect on mental health and the neurotropic potential of SARS- 
CoV-2 but also the associated psychosocial impacts of restrictions 
placed on large populations (Pfefferbaum and North, 2020; Vindegaard 
and Benros, 2020; Xiong et al. 2020). Set against a background where 
antidepressant prescribing is reportedly rising amid concerns expressed 
that this represents over-diagnosis of depression and over-use of anti-
depressants; it will be necessary to determine whether COVID-19 im-
pacts on diagnoses and treatment of mental health conditions. To enable 
future research into treatment and interventions for mental health, it is 
essential to understand what the baseline was pre-COVID-19. Therefore, 
we have investigated antidepressant prescribing practice for 5 years 
immediately preceding COVID-19 from January 2015-December 2019 
in England. Using the Open Prescribing database (OpenPrescribing.net, 
EBM DataLab, University of Oxford, 2021), we have performed a 
retrospective analysis of anonymised data on medicines prescribed by 
GPs. We have examined the most prescribed antidepressants, identified 
whether this reflects prescribing guidelines by clinical commissioning 
group (CCGs) and variations in local formularies. CCGs commission 
most of the hospital and community National Health Service (NHS) 
services in the local areas for which they are responsible. To provide a 
context for the antidepressant prescribing trends, we also considered 
prescribing levels for cardiovascular medicines, as a comparison with 
prevalent physical health condition prescribing. 
2. Methods 
The Open Prescribing database (OpenPrescribing.net, EBM DataLab, 
University of Oxford, 2021) was used to gather prescribing information 
in England across five years preceding COVID-19 from January 2015 to 
December 2019. The database contains anonymised data about medi-
cines prescribed as prescription items (a single supply of a medicine 
prescribed on a prescription form), quantity and cost incurred. The data 
includes prescriptions written by GPs and other non-medical prescribers 
(such as nurses, pharmacists, optometrists, chiropodists and potentially 
radiographers) who are attached to practices. The data does not cover 
private prescriptions. Where prescribing cannot be linked to a practice 
the data is excluded and amounts to approximately 0.2% of dispensed 
items. No information is provided on the duration of treatment, patient 
diagnosis or quantity of medicine prescribed (NHS Digital, 2018). Pre-
scribing data is from the monthly files published by NHS Business Ser-
vices Authority (NHSBSA), used under the terms of the Open 
Government Licence. 
All antidepressants were identified in the Open Prescribing database 
using the British National Formulary (BNF) (Joint Formulary Commit-
tee, 2020) (Supplementary Table 2). For each antidepressant, monthly 
information was categorised as: name of clinical commissioning group 
(CCG), month of prescribing, total items prescribed, total quantity of 
tablets and total cost incurred by CCG and compiled in a spreadsheet 
which was then exported to Microsoft Access 365 for analysis. The top 
10 most prescribed antidepressants, in terms of total numbers of items 
prescribed, were identified by summing the number of items prescribed 
for each antidepressant across the whole study period 2015 to 2019 and 
ranking them. Similar prescribing data were also extracted on the top 10 
most prescribed cardiovascular medicines. 
Due to merging and/or creation of new CCGs in 2020, the number of 
CCGs went from 191 (2015–2018) to 135 (in 2019) in the Open- 
Prescribing database to accommodate this change. Therefore, where 
we have analyzed prescribing trends by CCG, we have only examined 
the 118 CCGs that remained unchanged throughout the analysis period 
(2015–2019). To examine variations in prescribing across CCGs in En-
gland, and to identify CCGs for further analysis, the number of pre-
scription items for the top 5 most prescribed antidepressants 
(citalopram, amitriptyline, sertraline, mirtazapine and fluoxetine) was 
summed for each CCG. Population estimates for each CCG were obtained 
from the Office for National Statistics and the mid-2018 values used to 
adjust data for population size (Office for National Statistics, 2019). The 
top 10 and the lowest 10 antidepressant prescribing CCGs, in terms of 
total items prescribed/population of CCG, were identified. Local CCG 
formularies for each of these 20 CCGs, obtained from the relevant CCG’s 
or the equivalent netFormulary platform, were used to identify any 
differences in antidepressant prescribing guidance across the CCGs. 
To identify whether socioeconomic factors might contribute to dif-
ferences in prescribing practice, the 2019 index of multiple deprivation 
(IMD) average scores were obtained for each CCG (Oxford Consultants 
for Social Inclusion, 2019). The IMD score is a relative measure of 
deprivation incorporating education, income, employment, health and 
crime facets. 
2.1. Statistical analysis 
InVivo Stat 3.7.0.0 software was used to summarise and analyse the 
data (Clark et al., 2012). A linear regression analysis was used to 
investigate the relationship between IMD score and items pre-
scribed/population with Pearson’s correlation coefficient used as a 
measure of the strength of the association. Linear regressions were also 
used to evaluate the change in items prescribed over time and by region 
of England. 
3. Results 
We found a 25% increase in the annual number of the 10 most 
prescribed antidepressant items in England, from 58 to 72 million 
2015–2019 (Table 1, Fig. 1). All of these are generic medicines and 
account for 96% of all antidepressant prescribing. The selective sero-
tonin reuptake inhibitor (SSRI) citalopram was the most popular anti-
depressant prescribed with over 71 million items in 5 years (Table 1, 
Fig. 1). The number of prescriptions for the SSRI sertraline increased 
every year, from 9.3 to 16.7 million in 2019. Over the same period, 
Table 1 
The 10 most prescribed antidepressant and cardiovascular medicines in England 
2015–2019.  
Antidepressant Drug Class Total items 
prescribed 
Total cost (£) 
Citalopram SSRI 71,177,723 88,775,221 
Amitriptyline TCA 65,908,492 122,208,111 
Sertraline SSRI 64,619,046 92,896,634 
Mirtazapine Other 40,722,592 68,983,897 
Fluoxetine SSRI 32,928,229 63,428,155 
Venlafaxine SNRI 20,513,043 181,241,748 
Duloxetine SNRI 10,281,654 91,508,884 
Paroxetine SSRI 6,929,370 25,822,303 
Trazodone Other 5,588,382 107,441,782 
Escitalopram SSRI 5,219,690 12,928,482 
Atorvastatin Lipid regulating drug 184,496,120 269,222,364 
Ramipril ACE inhibitor 140,035,650 210,994,193 
Amlodipine Calcium channel 
blocker 
139,431,269 184,955,330 
Simvastatin Lipid regulating drug 138,347,044 154,214,122 
Aspirin Antiplatelet (COX 1 
inhibitor) 
124,613,771 102,131,695 
Bisoprolol fumarate β blocker 111,419,052 107,395,429 
Furosemide Loop diuretic 60,773,842 72,411,390 
Bendroflumethiazide Thiazide diuretic 55,706,038 47,572,919 
Losartan potassium Angiotensin receptor 
blocker 
47,220,853 118,916,648 
Warfarin sodium Anticoagulant 47,213,118 73,855,343 
Antidepressants are listed in the top half and cardiovascular medicines in the 
bottom half of the table. All medicines are ranked in descending order according 
to the number of items prescribed. The drug class was obtained from the sum-
mary of product characteristics for the relevant medicine. ACE (angiotensin 
converting enzyme), COX-1 (cyclooxygenase 1), SSRI (Selective serotonin re-
uptake inhibitor), SNRI (serotonin noradrenaline reuptake inhibitor), TCA 
(Tricyclic antidepressant). 
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prescriptions for mirtazapine (an atypical antidepressant acting as pre-
synaptic α2 adrenergic receptor antagonist, also known as a noradren-
ergic and specific serotonergic antidepressant (NaSSA)) increased from 
6.7 to 9.6 million. The annual increase in prescriptions of sertraline was 
at a quicker rate than mirtazapine; the number of sertraline items pre-
scribed increased by on average 2 million year on year, 2.7 times higher 
than the mirtazapine annual rise (increasing by 0.7 million items per 
year) (Fig. 1). Other antidepressants were prescribed at almost constant 
levels year on year. 
Despite an increase in antidepressant items prescribed, we found an 
overall 27.8% decrease in the cost incurred for prescribing these 10 
antidepressants from £202 million (2015) to £146 million (2019). The 
total cost incurred data does not account for how drug costs in primary 
care may have fluctuated for any item and therefore the overall trend 
may mask differing trends for individual drugs. Fig. 2 shows the total 
cost and the number of items prescribed for each of the top 10 antide-
pressants, cumulatively 2015-2019. Citalopram is one of the cheapest 
antidepressants (£89 million) and has the highest number of items 
prescribed over 5 years (71 million). On the other hand, venlafaxine is 
the most expensive antidepressant in terms of costs incurred (£181 
million) but has one of the lowest total number of items prescribed over 
5 years (21 million) (Fig. 2, Table 1). 
We investigated whether there were variations in antidepressant 
prescribing across CCGs. The number of items for the 5 most prescribed 
antidepressants (accounting for 82% of total antidepressant items pre-
scribed) was adjusted to account for the population of each CCG and 
then ranked. On this basis, the top 10 (high antidepressant prescribing) 
and the bottom 10 (low antidepressant prescribing) CCG’s were selected 
for further analysis. The mean (+/- SD) increase in antidepressant pre-
scribing was 27.3% +/- 6.4% for the top 10 antidepressant prescribing 
CCGs, compared to 24.6% +/- 6.5% for the bottom 10 CCGs over the full 
5-year study period (2015–2019) (Table 2). Citalopram, amitriptyline 
and sertraline were the most prescribed antidepressants in each of the 
CCGs. The only exception was Brent CCG where amitriptyline was the 
most prescribed antidepressant during the study period 2015–2018 but 
this was overtaken by sertraline in 2019. For both the highest 10 and 
Fig. 1. Annual number of prescription items for the 10 most prescribed antidepressants in England 2015–2019. Antidepressants are ranked from left to right ac-
cording to the greatest number of items prescribed in each calendar year. 
Fig. 2. Total cost (line graph) and total items prescribed (columns) for the 10 most prescribed antidepressants in England 2015–2019.  
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lowest 10 antidepressant prescribing CCGs, sertraline prescriptions are 
rising reflecting the national picture (Fig. 1). For example, in Knowsley 
(top 10) and Hounslow (bottom 10), citalopram was the most prescribed 
antidepressant in 2015/2016 but it was overtaken by sertraline in 2018/ 
2019. Across these 20 CCGs, local formularies providing guidance on 
antidepressant prescribing were found to be broadly similar. Sertraline, 
fluoxetine and citalopram are the first line treatments of choice in a 
patient with depression. Mirtazapine is a second-line treatment in pa-
tients not responding to, or that cannot tolerate, the SSRI treatments. 
Exceptions to this general agreement amongst the CCGs are shown in 
Supplementary Table 1. 
We used the IMD score to rank 118 CCGs to look at the influence of 
socioeconomic factors on antidepressant prescribing. The higher the 
IMD score, the more deprived the area is (e.g. Blackpool CCG IMD score 
= 45.04), and the higher the rank (close to 1) of the CCG (e.g. Blackpool 
is ranked 2). Table 2 shows the IMD score for CCGs with the highest and 
lowest levels of antidepressant prescribing. When the number of anti-
depressant items for only the 5 most prescribed antidepressants is 
considered, adjusted to account for population, there are 5 times as 
many antidepressant prescriptions in Blackpool than in Redbridge 
Table 2 
Characteristics of clinical commissioning groups (CCGs) with highest (top 10) and lowest (bottom 10) numbers, cumulatively, of the 5 most prescribed antidepressant 
items/ population of CCG in England 2015–2019.  
CCG name Total items prescribed cumulatively for top 5 
antidepressants1 
% increase in AD 
prescribing2 
Population3 IMD average 
score4 
Rank of IMD average 
score5 
Items/ population of 
CCG6 
Blackpool 1,428,981 20.7 139,305 45.04 2 10.26 
Sunderland 2,484,968 40.1 277,417 30.59 30 8.96 
Barnsley 2,039,857 30.2 245,199 29.93 32 8.32 
South Tyneside 1,177,825 27.7 150,265 31.51 24 7.84 
North Tyneside 1,579,118 24.9 205,985 22.28 85 7.67 
Knowsley 1,137,808 22.5 149,571 43.01 3 7.61 
St Helens 1,328,490 27.5 180,049 31.52 23 7.38 
Newcastle 
Gateshead 
3,698,904 27.9 502,704 29.15 39 7.36 
Salford 1,844,764 18.0 254,408 34.21 12 7.25 
Hull 1,844,619 33.1 260,645 40.56 5 7.08 
Hillingdon 845,994 18.8 304,824 18.22 120 2.78 
Hounslow 749,529 26.0 270,782 21.49 94 2.77 
Newham 932,844 32.3 352,005 29.58 34 2.65 
Ealing 905,920 37.4 341,982 22.71 78 2.65 
Waltham Forest 659,944 21.5 276,700 25.21 64 2.39 
West London 535,363 19.1 226,099 22.35 84 2.37 
City and Hackney 669,171 24.4 288,371 32.09 21 2.32 
Brent 725,697 21.7 330,795 25.56 62 2.19 
Harrow 547,811 16.8 250,149 15.03 151 2.19 
Redbridge 626,867 28.4 303,858 17.20 131 2.06  
1 The 5 most prescribed antidepressants are citalopram, amitriptyline, sertraline, mirtazapine and fluoxetine. 2 Antidepressant (AD) prescribing in 2019 as a % of 
2015 values.3 Mid-2018 population estimates for CCGs in England from the Office for National Statistics.4The Index of Multiple Deprivation (IMD) average scores for 
2019 for each CCG. 5 Ranking of IMD average score across all CCGs out of 191. The higher the IMD average score (e.g. 45.04), the lower the rank of average score (e.g. 
2), and the more deprived a particular CCG area is. 6 Calculated by the formula: total items cumulatively for 5 most prescribed antidepressants per CCG divided by CCG 
population. 
Fig. 3. Correlation between total items prescribed (2015–2019) cumulatively for the 5 most prescribed antidepressants/population of CCG and CCG IMD average 
score in 118 CCGs in England. The line of best fit indicating the correlation is shown. IMD (Index of Multiple Deprivation), CCGs (clinical commissioning groups). 
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(Table 2). Looking across all 118 CCGs (Fig. 3), the IMD score is posi-
tively correlated with the cumulative number of antidepressant pre-
scription items (Pearson’s coefficient = 0.412, P < 0.0001). For every 
one-point increase in the IMD score, the number of antidepressant items 
prescribed per population of CCG increases by 0.08. 
To provide context for the antidepressant data, Table 1 also shows 
the 10 most prescribed cardiovascular medicines in the same study 
period. The total items prescribed cumulatively for the 10 most pre-
scribed cardiovascular medicines account for 65% of all cardiovascular 
prescribing and increased by 2.75% from 207 million (2015) to 213 
million (2019). At the same time, the total cost incurred dropped by 
3.8% from £295 million (2015) to £284 million (2019) (Table 1). Results 
from linear regression analyses (Supplementary Table 3) show that eight 
of the 10 antidepressants included had a mean increase in items pre-
scribed over time whereas only five of the cardiovascular drugs showed 
increases. Comparing prescribing between regions of England indicated 
that almost all antidepressants in all regions of England were prescribed 
more than in London (Supplementary Table 4a). For cardiovascular 
medicines the picture was more mixed with some areas prescribing more 
of one medication than the London region while others prescribed at a 
lower frequency (Supplementary Table 4b). 
Overall, there were 5.522 billion items dispensed in the community 
in England 2015–19, at a total cost of £45.5 billion (Table 3). The 10 
most prescribed antidepressant items represent 5.87% of the total items 
dispensed, at a cost of £0.9 billion or 1.88% of the total cost (Table 3). 
NHSBSA (2020) data showed that citalopram (#15,#16), amitriptyline 
(#18,#17), and more recently sertraline (#17–#14 in 2017–2019) have 
been in the top 20 most prescribed items for all medicines in England 
from 2015–2019. For the 10 most prescribed cardiovascular medicines, 
over the study period, there were 3.2 times more cardiovascular pre-
scription items than the number of antidepressant items, accounting for 
19% of the total items dispensed. NHSBSA data also showed that sim-
vastatin (#1) was the most prescribed medicine in 2015, overtaken by 
atorvastatin in 2016-2019 with 45.8 million prescription items in 2019 
alone. This is expected given that in England 14% of adults aged 16 and 
over reported having had any doctor-diagnosed cardiovascular disease 
in 2017 (Scholes and Mindell, 2018), unchanged since 2011, whereas 
depression prevalence is 3.8% of the population (McManus et al., 2016). 
4. Discussion 
We found that antidepressant prescribing for the 10 most prescribed 
antidepressants in England has risen 25% from 58 million in 2015 to 72 
million in 2019. These 10 antidepressants account for 96% of all anti-
depressant prescribing. Of the top 10 most prescribed antidepressants, 
the SSRI citalopram was the number one item prescribed and between 
2015–2019 was among the top 20 most prescribed medicines in England 
across all prescription items. The rise in antidepressant prescribing is 
likely accounted for by rising year on year prescriptions for sertraline 
and mirtazapine. Most other antidepressants were prescribed at com-
parable levels year on year. Over the same period the cost of antide-
pressant prescribing has fallen 27.8%. This fall in prescription costs may 
be due to a competitive generics market facilitating the supply of lower 
cost generic medicines to the NHS (Andalo, 2019). 
Strengths and limitations 
Presenting antidepressant prescribing data in isolation may create 
the unwarranted impression that antidepressant prescribing outstrips all 
other medications. A strength of this study is that we have reported 
antidepressant prescribing trends alongside physical health prescribing. 
This reduces the risk of stigmatizing antidepressant use which is a sig-
nificant deterrent to patients seeking help and treatment (Castaldelli--
Maia et al., 2011; Nutt et al., 2014; Arnaez et al., 2020). Between 2006 
and 2016, the number of cardiovascular prescriptions grew by 36.2% to 
around 320 million items, while the number for the central nervous 
system increased by 60.1% to about 207 million (Ewbank et al., 2018). 
We have shown that prescribing for the 10 most prescribed cardiovas-
cular medicines accounts for 19%, while the 10 most prescribed anti-
depressants accounts for 5.9%, of all prescription items in England 
2015–2019. The total cost incurred for the 10 most prescribed cardio-
vascular medicines is 2.95% and for the 10 most prescribed antide-
pressants is 1.88% of the total prescription costs. This is an 
underestimate of prescribing for cardiovascular medicine as the top 10 
cardiovascular medicines represents only 65% of all cardiovascular 
medicines while the top 10 antidepressants represent 96% of all anti-
depressant prescribing. 
A limitation of using the Open Prescribing database is that pre-
scribing information is not linked to patients. So, while it is useful for 
identifying prescribing trends, on a group level, we cannot identify pa-
tient numbers nor characteristics nor indication the medicine is pre-
scribed for, nor the duration or quantity of the medicine prescribed. 
Antidepressants are used in other disorders, for example neuropathic 
pain (amitryptyline), urinary incontienence (duloxetine) and high levels 
of amitryptiline prescribing may reflext a high incidence of neuropathic 
pain, rather than any change in antidepressant prescribing per se. Using 
Table 3 
Comparison of antidepressant and cardiovascular prescribing as a proportion of the total number of items and cost for prescriptions in England 2015–2019.  






Total AD items 
dispensed 
(Millions)2 
Total cost AD 
items 
(£Millions)3 








Total CV items 
dispensed 
(Millions)6 
Total cost CV 
items 
(£Millions)7 








2015 1,084 9,267 58 202 5.32 2.18 207 295 19.11 3.19 
2016 1,104 9,205 62 185 5.57 2.01 209 257 18.92 2.79 
2017 1,106 9,167 65 171 5.84 1.87 210 268 18.95 2.92 
2018 1,109 8,831 68 152 6.14 1.72 211 237 19.01 2.69 
2019 1,120 9,079 72 146 6.44 1.6 213 284 19.01 3.13 
Total 5,522 45,548 324 855 5.87 1.88 1,049 1,342 19 2.95  
1 Values obtained from the prescription cost analysis for England 2019 data from the NHS Business Services Authority – the additional analysis tables Table A1 (Total 
items, cost, number of items and cost per capita, 2014 to 2019).Values are rounded to the nearest million for ease of display. Available from; https://www.nhsbsa.nhs. 
uk/statistical-collections/prescription-cost-analysis/prescription-cost-analysis-england-2019 
2 Total items dispensed per calendar year for the top 10 antidepressants (AD) (Table 1) from the Open Prescribing Database. 
3 Total cost incurred for the top 10 antidepressants (AD) per calendar year from the Open Prescribing Database. 
4 Antidepressant (AD) prescribing (top 10 items prescribed) expressed as a percentage of the total items dispensed per calendar year. 
5 Cost of AD prescribing (top 10 items prescribed) per calendar year, expressed as a percentage of the total cost of prescribing in England. 
6 Total items dispensed per calendar year for top 10 prescribed cardiovascular (CV) medicines (Table 1) from the Open Prescribing Database. 
7 Total cost incurred per calendar year for top 10 prescribed cardiovascular (CV) medicines from the Open Prescribing Database. 
8 Cardiovascular (CV) prescribing (top 10 items prescribed) expressed as a percentage of the total items dispensed per calendar year. 
9 Cost of cardiovascular prescribing (CV) (top 10 items prescribed), per calendar year, expressed as a percentage of the total cost of prescribing in England. 
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a different database, the Clinical Practice Research Datalink (CPRD), 
where patient diagnoses are linked with prescriptions, an analysis of 
antidepressant prescribing has shown that 63% of antidepressant pre-
scribing was for depression, 38% for anxiety and 5% for neuropathic 
pain (Iwagami et al. 2017). The Open Prescribing database does not 
provide information on dosing. As low dose amitriptyline is likely used 
for pain rather than depression (Moore et al. 2015), dosing information 
may allow inferences to be made as to the indication for which 
amitriptyline was prescribed. 
This study has focused on group level analysis and interpretation of 
data and therefore there is no risk of committing ecological fallacy. We 
are not able to draw any conclusions about individual patients and any 
prescriptions they receive for antidepressants or cardiovascular disease 
medications or individual socioeconomic status. We have reported the 
CCG-level of antidepressant prescribing in this study and not prescribing 
at an individual patient or GP practice level. While this gives a good 
overview of prescribing of antidepressants in English CCGs, we 
emphasise that this is not at a GP practice or patient level data. Future 
studies will look at antidepressant prescribing in individual patients to 
understand more about how patients switch between different treat-
ments and length of treatment. Also, the IMD average score for 2019 
(most recent) has been used as a measure to assess deprivation and to 
explain variation in prescribing across different CCGs. IMD scores are 
released by the office of national statistics every 4 to 5 years so any 
variation of deprivation levels in the CCGs over the study period cannot 
be accounted for with this measure. 
Comparison with existing literature 
Our data are in line with previous reports showing increasing anti-
depressant prescribing in England for at least the last 10 years (Balin-
skaite, 2019) and a similar pattern is seen globally (for example, 
Gualano et al. 2014; Soleymani et al. 2018). One reason accounting for 
rising prescribing might be better treatment of patients, perhaps influ-
enced by prescribing guidance. In terms of the specific antidepressants 
being prescribed, our findings likely reflect adherence to key 
evidence-based prescribing guidelines which are incorporated into CCG 
formularies. Our analysis of a sample of CCG local formularies showed 
little difference between the highest and lowest antidepressant pre-
scribing CCGs. Sertraline prescriptions rose fastest of all the antide-
pressants and has been reported to have slightly higher efficacy than 
other SSRIs. NICE and British Association for Psychopharmacology 
(BAP) guidelines recommend the use of sertraline for patients with a 
co-morbid chronic physical health condition because of lesser chances of 
drug-drug interactions (NICE, 2009a; NICE, 2009b; Cleare et al., 2015). 
A study by Hoehn-Saric et al. (2000) showed that sertraline is more 
effective in patients with co-morbid depression and 
obsessive-compulsive-disorder. A meta-analysis of 59 studies by 
Cipriani et al. (2010) showed that sertraline has higher efficacy than 
fluoxetine and was tolerated better than mirtazapine, paroxetine and 
amitriptyline during acute phase of depression treatment. Furthermore, 
sertraline has proved effective in managing seasonal depression (Mos-
covitch et al., 2004). Prescriptions for mirtazapine are also rising year on 
year. An open multicentre study including 4771 patients with major 
depressive episode found that mirtazapine showed a significant and 
quicker reduction of suicidal thoughts than SSRIs (Lavergne et al., 
2005). This suggests that mirtazapine may be safer to use in depressed 
patients who are more prone to suicidal thoughts, such as adolescents 
(Strandheim et al., 2014). 
The level of antidepressant prescribing was influenced by the relative 
socio-economic deprivation in different regions, in line with previous 
reports on mental health treatments (Taylor et al., 2019; Von Soest et al., 
2012; Delphin-Rittmon et al., 2015; Giebel et al., 2020). Across 118 
CCGs in England, antidepressant prescribing levels, adjusted for popu-
lation, were positively correlated with the IMD average score. The de-
gree of scatter in the data point to additional factors influencing the 
volume of antidepressant prescribing. Additional socio-economic factors 
that have been linked to antidepressant prescribing include employment 
status, educational achievement, perceived social class, patient age and 
sex (Butterworth et al., 2013; Lewer et al., 2015; Halonen et al., 2018). 
Our analysis identified that high antidepressant prescribing CCGs are 
geographically located in the North West and North East of England, 
whereas the low prescribing CCGs are in the greater London area, 
similar to other studies (Balinskaite, 2019). Antidepressant prescribing 
has also been identified to be higher in urban locations than in rural 
areas (Grigoroglou et al., 2020; Morrison et al., 2009). These factors 
have a complex interplay affecting antidepressant prescribing. 
Implications for research and/or practice 
Antidepressant prescribing is increasing in England, specifically 
sertraline and mirtazapine, in line with clinical guidelines. While rela-
tive socio-economic deprivation is a contributing factor, it is not clear 
what is driving this increase. Whether the rise in antidepressant pre-
scribing seen here reflects changes in the recognition and treatment of 
depression in primary care or a higher prevalence of depression, or a 
combination of these factors, remains to be determined. Additionally, 
the risk of significant withdrawal effects on stopping antidepressant 
treatment remains a concern and a potential contributary factor to 
increasing levels of prescribing (Davies and Read, 2019; Taylor et al. 
2019). Reflecting these concerns, the National Institute for Health and 
Care Excellence has updated its guidance to recognize the severity and 
length of antidepressant withdrawal (NICE, 2009a). 
In conclusion, given the potential concerns of the impact of COVID- 
19 on mental health, this pre-COVID-19 analysis provides a baseline 
against which to assess antidepressant prescribing in the future. Recent 
reports suggest that the number of antidepressant prescriptions made in 
general practice in the 6 months from April 1st 2020 was 3.9% higher 
than the corresponding period in 2019 (Armitage, 2021). However, 
whether this increase reflects changes during the pandemic or whether it 
reflects the year on year increase in antidepressant prescribing remains 
to be determined (Walker et al. 2021). 
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